Literature DB >> 2328190

Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism.

R J Guttendorf1, M Britto, R A Blouin, T S Foster, W John, K A Pittman, P J Wedlund.   

Abstract

1. The phenotyping parameters for dextromethorphan and mephenytoin were assessed in 48 normal male volunteers following administration of each metabolic probe drug on separate occasions and together according to a randomized 3-way crossover design. 2. Neither the urinary S-/R-mephenytoin ratio nor the dextromethorphan metabolic ratio were altered significantly by coadministration of the probe drugs. 3. Five-hundred and nineteen subjects were screened for expression of mephenytoin 4-hydroxylase and dextromethorphan O-demethylase activity following the coadministration of mephenytoin and dextromethorphan. The activity was determined in each case by methods not requiring any quantitative measurements. 4. Nineteen (3.7%) of the subjects were identified as poor metabolizers (PMs) of mephenytoin and 35 subjects (6.7%) as PMs of dextromethorphan. 5. All PMs of dextromethorphan were confirmed by more rigorous evaluation of the metabolic ratio.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2328190      PMCID: PMC1380105          DOI: 10.1111/j.1365-2125.1990.tb03653.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  38 in total

1.  Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22.

Authors:  M Eichelbaum; M P Baur; H J Dengler; B O Osikowska-Evers; G Tieves; C Zekorn; C Rittner
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

2.  Mephenytoin hydroxylation in the Cuna Amerindians of Panama.

Authors:  T Inaba; L F Jorge; T D Arias
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

3.  Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors.

Authors:  A Kaisary; P Smith; E Jaczq; C B McAllister; G R Wilkinson; W A Ray; R A Branch
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

4.  Human-liver cytochromes P-450 involved in polymorphisms of drug oxidation.

Authors:  F P Guengerich; L M Distlerath; P E Reilly; T Wolff; T Shimada; D R Umbenhauer; M V Martin
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908

5.  The genetic defect of mephenytoin hydroxylation.

Authors:  W Kalow
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908

Review 6.  Variability in drug metabolism: importance of genetic constitution.

Authors:  J H Schellens; D D Breimer
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

7.  MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation.

Authors:  R Fonne-Pfister; M J Bargetzi; U A Meyer
Journal:  Biochem Biophys Res Commun       Date:  1987-11-13       Impact factor: 3.575

8.  Polymorphism of dextromethorphan oxidation in a French population.

Authors:  D Larrey; G Amouyal; M Tinel; P Letteron; A Berson; G Labbe; D Pessayre
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

9.  High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.

Authors:  T Kronbach; D Mathys; J Gut; T Catin; U A Meyer
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

10.  Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.

Authors:  L A Siddoway; K A Thompson; C B McAllister; T Wang; G R Wilkinson; D M Roden; R L Woosley
Journal:  Circulation       Date:  1987-04       Impact factor: 29.690

View more
  11 in total

Review 1.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

2.  Polymorphisms in oxidative drug metabolism: relationship to food preference.

Authors:  M R Britto; H E McKean; G G Bruckner; P J Wedlund
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

Review 3.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

4.  Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan.

Authors:  N E Basci; A Bozkurt; S O Kayaalp; A Sayal; A Isimer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jan-Mar       Impact factor: 2.441

5.  Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies.

Authors:  Y Zhang; R A Blouin; P J McNamara; J Steinmetz; P J Wedlund
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

6.  Frequency of S-mephenytoin hydroxylation deficiency in 373 Spanish subjects compared to other Caucasian populations.

Authors:  J Reviriego; L Bertilsson; J A Carrillo; A Llerena; M J Valdivielso; J Benítez
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 7.  Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19.

Authors:  D A Flockhart
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

8.  Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin.

Authors:  D A Smith; M H Chandler; S I Shedlofsky; P J Wedlund; R A Blouin
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

9.  Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population.

Authors:  R Setiabudy; M Kusaka; K Chiba; I Darmansjah; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

Review 10.  Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping.

Authors:  R T Coutts
Journal:  J Psychiatry Neurosci       Date:  1994-01       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.